- Altria adjusted its full-year earnings per share (EPS) forecast, now expecting $5.35 to $5.45, up from $5.30 to $5.45 previously, with market estimates at $5.38.
- Second quarter revenue, excluding excise taxes, was $5.29 billion, marking a slight increase of 0.2% year-over-year, surpassing the estimated $5.2 billion.
- Revenue from smokeable products, after excise taxes, was $4.57 billion, slightly declining by 0.4% year-over-year, but higher than the estimated $4.53 billion.
- Oral tobacco products revenue, net of excise taxes, grew by 6% year-over-year to $728 million, exceeding the estimated $710.5 million.
- Adjusted EPS for the second quarter was $1.44, an increase from $1.31 in the prior year, and higher than the estimated $1.39.
- The adjusted operating income (OCI) for smokeable products reached $2.95 billion, up 4.2% year-over-year, above the estimated $2.84 billion.
- Oral tobacco adjusted OCI increased by 11% year-over-year to $500 million, beating the estimated $480.4 million.
- Cigarette shipment volume was consistent with estimates at 16.07 billion sticks, but still represented a 10.2% decline.
- Cigar shipment volume totaled 479 million sticks, exceeding the estimate of 457.2 million, reflecting a 3.7% increase.
- Oral tobacco shipment volume was 198.6 million cans and packs, slightly above the estimate of 198.57 million, but reflecting a 1% decrease.
- Analyst consensus included 4 buys, 10 holds, and 3 sells.
Altria Group on Smartkarma
On Smartkarma, independent analysts like Baptista Research have been covering Altria Group, providing insights into the company’s recent performance and strategic moves. In one report titled “Altria Group: An Insight Into Recent Macroeconomic Pressures & Its Consumer Pricing Strategy!” by Baptista Research, Altria’s first-quarter performance in 2025 was discussed in the context of market dynamics. The CEO highlighted the company’s profitability in the traditional tobacco business and the resilience of its flagship brand, Marlboro, despite economic challenges.
Another report by Baptista Research, “Altria’s Secret Weapon: How This Tobacco Giant Keeps Winning Despite Shrinking Cigarette Sales!“, focused on Altria’s fourth quarter and full-year 2024 earnings. The company showed strong financial results, driven by its core tobacco operations. Altria’s consistent growth in adjusted diluted earnings per share (EPS) and its commitment to returning capital to shareholders through dividends and share repurchases were highlighted as key factors in its success.
A look at Altria Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 5 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Altria Group, Inc., a leading holding company known for its tobacco products and brewery interests, boasts strong scores in key areas according to Smartkarma Smart Scores. With a top score in both Dividend and Growth, Altria demonstrates a commitment to rewarding investors while seeking opportunities for expansion. Additionally, its high scores in Resilience show the company’s ability to weather various market conditions adeptly. Although Momentum scored slightly lower, the overall outlook for Altria Group appears positive as it continues to focus on dividends, growth, and resilience.
Overall, Altria Group‘s Smartkarma Smart Scores highlight a favorable long-term outlook for the company. Its impressive scores in Dividend, Growth, and Resilience indicate a strong foundation for sustained performance and shareholder value. With its focus on manufacturing and selling tobacco products alongside interests in the brewery sector, Altria remains a key player in its industry, poised for continued success in the years ahead based on the analysis provided.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
